| |
| |
| Exchange: |
N/A |
| Security
Type: |
N/A |
| Shares
Out: |
13,920,000 |
| Market
Cap: |
6.75(M) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$0.4651 - $8.29 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile BioVie is a clinical-stage company developing drug therapies to overcome unmet medical needs in chronic debilitating conditions. In liver disease, Co.'s orphan drug candidate, BIV201 (continuous infusion terlipressin), is being developed as a future treatment option for patients suffering from ascites and other life-threatening complications of liver cirrhosis caused by nonalcoholic steatohepatitis, hepatitis, and alcoholism. In neurodegenerative disease, Co.'s product candidate, NE3107, is an orally administered small molecule that is thought to inhibit inflammation-driven insulin resistance and primary pathological inflammatory cascades with a mechanism of action.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
10,000 |
20,000 |
20,000 |
20,000 |
| Total Buy Value |
$0 |
$17,800 |
$17,800 |
$17,800 |
| Total People Bought |
1 |
1 |
1 |
1 |
| Total Buy Transactions |
1 |
2 |
2 |
2 |
| Total Shares Sold |
0 |
75,680 |
106,029 |
117,013 |
| Total Sell Value |
$0 |
$127,899 |
$259,122 |
$352,703 |
| Total People Sold |
0 |
1 |
2 |
2 |
| Total Sell Transactions |
0 |
1 |
5 |
7 |
| End Date |
2024-01-28 |
2023-10-27 |
2023-04-28 |
2022-04-28 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Do Cuong V |
President & CEO |
• • – |
2024-03-04 |
4 |
B |
$0.00 |
$0 |
I/I |
10,000 |
435,854 |
2.58 |
-54% |
|
| Kim Joanne Wendy |
Chief Financial Officer |
• – – |
2023-12-11 |
4 |
A |
$0.00 |
$0 |
D/D |
5,000 |
44,148 |
|
- |
|
| Gorlin Steve |
Director |
– • – |
2023-12-01 |
4 |
S |
$1.69 |
$127,899 |
D/D |
(75,680) |
46,358 |
|
70% |
|
| Do Cuong V |
President & CEO |
• • – |
2023-11-30 |
4 |
B |
$1.78 |
$17,800 |
D/D |
10,000 |
68,759 |
2.81 |
-72% |
|
| Hariri Robert J |
Director |
– • – |
2023-11-09 |
4 |
A |
$0.00 |
$0 |
D/D |
42,254 |
42,254 |
|
- |
|
| Gorlin Steve |
Director |
– • – |
2023-11-09 |
4 |
A |
$0.00 |
$0 |
D/D |
46,358 |
122,038 |
|
- |
|
| Berman Richard J |
Director |
– • – |
2023-11-09 |
4 |
A |
$0.00 |
$0 |
D/D |
51,830 |
69,235 |
|
- |
|
| Rogich Sigmund |
Director |
– • – |
2023-11-09 |
4 |
A |
$0.00 |
$0 |
D/D |
42,254 |
42,254 |
|
- |
|
| Gorlin Steve |
Director |
– • – |
2023-09-05 |
4 |
S |
$3.05 |
$26,108 |
D/D |
(8,560) |
75,680 |
|
59% |
|
| Berman Richard J |
Director |
– • – |
2023-08-22 |
4 |
S |
$3.50 |
$37,827 |
D/D |
(10,805) |
16,789 |
|
65% |
|
| Do Cuong V |
CEO & President |
• • – |
2023-06-29 |
4 |
A |
$0.00 |
$0 |
I/I |
149,500 |
425,854 |
|
- |
|
| Do Cuong V |
CEO & President |
• • – |
2023-06-21 |
4 |
OE |
$0.00 |
$0 |
I/I |
41,506 |
271,401 |
|
- |
|
| Berman Richard J |
Director |
– • – |
2023-06-07 |
4 |
S |
$5.81 |
$34,782 |
D/D |
(5,984) |
23,210 |
|
40% |
|
| Berman Richard J |
Director |
– • – |
2023-05-22 |
4 |
S |
$6.50 |
$32,506 |
D/D |
(5,000) |
29,194 |
|
49% |
|
| Berman Richard J |
Director |
– • – |
2023-03-28 |
4 |
S |
$8.52 |
$64,870 |
D/D |
(7,613) |
34,194 |
|
55% |
|
| Berman Richard J |
Director |
– • – |
2023-03-27 |
4 |
S |
$8.52 |
$28,711 |
D/D |
(3,371) |
41,807 |
|
51% |
|
| Markham Penelope |
EVP Liver Cirrhosis R&D |
• – – |
2023-02-16 |
4 |
D |
$6.12 |
$15,153 |
D/D |
(2,476) |
47,841 |
|
- |
|
| Kim Joanne Wendy |
Chief Financial Officer |
• – – |
2023-02-16 |
4 |
D |
$6.12 |
$15,153 |
D/D |
(2,476) |
39,148 |
|
- |
|
| Reading Christopher |
EVP Neuroscience R&D |
• – – |
2023-02-16 |
4 |
D |
$6.12 |
$15,153 |
D/D |
(2,476) |
37,148 |
|
- |
|
| Do Cuong V |
CEO & President |
• • – |
2023-02-16 |
4 |
D |
$6.12 |
$30,312 |
I/I |
(4,953) |
229,895 |
|
- |
|
| Ahlem Clarence N. |
EVP Neuroscience Product Dev. |
• – – |
2023-02-16 |
4 |
D |
$6.12 |
$15,153 |
D/D |
(2,476) |
37,148 |
|
- |
|
| Palumbo Joseph M |
Chief Medical Officer |
• – – |
2023-02-16 |
4 |
D |
$6.12 |
$15,153 |
D/D |
(2,476) |
37,148 |
|
- |
|
| Do Cuong V |
CEO & President |
• • – |
2022-11-23 |
4 |
A |
$0.00 |
$0 |
I/I |
79,248 |
234,848 |
|
- |
|
| Berman Richard J |
Director |
– • – |
2022-11-23 |
4 |
A |
$0.00 |
$0 |
D/D |
43,578 |
45,178 |
|
- |
|
| Ahlem Clarence N. |
EVP Neuroscience Product Dev. |
• – – |
2022-11-23 |
4 |
A |
$0.00 |
$0 |
D/D |
39,624 |
39,624 |
|
- |
|
82 Records found
|
|
Page 1 of 4 |
|
|
